https://www.selleckchem.com/
012). Pirfenidone treatment significantly decreased the Kyn/Trp ratio (0.030 ± 0.011 baseline vs 0.025 ± 0.010 post-treatment, = 0.048) whilst nintedanib treatment significantly increased blood GSH (486 ± 70 μmol/L vs 723 ± 194 μmol/L, = 0.006) and reduced ADMA concentrations (0.501 ± 0.094 vs. 0.468 ± 0.071 μmol/L, = 0.024). pirfenidone and nintedanib exert beneficial effects on specific markers of oxidative stress and inflammation in IPF patients. pirfenidone and nintedanib exert beneficial effects on specific markers of oxidative stress and inflammation